(0.10%) 5 522.75 points
(0.14%) 39 898 points
(0.22%) 19 794 points
(-0.02%) $81.61
(0.68%) $2.83
(-0.29%) $2 337.50
(0.17%) $29.58
(0.30%) $1 004.80
(0.02%) $0.932
(-0.05%) $10.53
(0.00%) $0.788
(-0.84%) $87.26
31.87% $ 0.277
Live Chart Being Loaded With Signals
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer...
Stats | |
---|---|
Dzisiejszy wolumen | 51.30M |
Średni wolumen | 2.13M |
Kapitalizacja rynkowa | 1.65M |
EPS | $-2.65 ( Q2 | 2023-03-14 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0136 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.108 (38.96%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-02-09 | Delaversano Robert J | Sell | 40 | Common Stock |
2022-11-04 | Delaversano Robert J | Sell | 283 | Common Stock |
2022-10-07 | Foster Spahr Stephany | Buy | 50 000 | Stock Option (right to buy) |
2022-10-07 | Foster Spahr Stephany | Buy | 0 | |
2022-08-05 | Delaversano Robert J | Sell | 284 | Common Stock |
INSIDER POWER |
---|
97.76 |
Last 87 transactions |
Buy: 13 356 389 | Sell: 519 303 |
Wolumen Korelacja
OncoSec Medical Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
OncoSec Medical Inc Korelacja - Waluta/Towar
OncoSec Medical Inc Finanse
Annual | 2022 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-19.13 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-19.13 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-30.20 |
FY | 2020 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-56.22 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
OncoSec Medical Inc
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej